Unexpected binding orientation of bulky-B-ring anti-androgens and implications for future drug targets

Journal of Medicinal Chemistry

Volumn 54, Issue 11, 2011, Pages 3973-3976

  Duke III, Charles B ^a   Jones, Amanda ^b   Bohl, Casey E ^b   Dalton, James T ^b   Miller, Duane D ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b GTx Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 CYANO 1 NAPHTHOTHIONITRILE; ANDROGEN RECEPTOR ANTAGONIST; ANDROSTANOLONE; BICALUTAMIDE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG POTENCY; DRUG TARGETING; STRUCTURE ANALYSIS; X RAY CRYSTALLOGRAPHY;

ANDROGEN ANTAGONISTS; ANDROGEN RECEPTOR ANTAGONISTS; ANDROGENS; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MOLECULAR STRUCTURE; MOLECULAR TARGETED THERAPY; PROSTATIC NEOPLASMS; PROTEIN BINDING; RECEPTORS, ANDROGEN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79958077907     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm2000097     Document Type: Article

References (11)

1. Hara, T.; Miyazaki, J.-i.; Araki, H.; Yamaoka, M.; Kanzaki, N.; Kusaka, M.; Miyamoto, M. Novel mutations of androgen receptor: A possible mechanism of bicalutamide withdrawal syndrome. Cancer Res. 2003, 63 (1), 149-153. (Pubitemid 36070433)
2. Suzuki, H.; Akakura, K.; Komiya, A.; Aida, S.; Akimoto, S.; Shimazaki, J. Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: Relation to antiandrogen withdrawal syndrome. Prostate 1996, 29 (3), 153-158. (Pubitemid 26341820)
3. Kim, J.; Wu, D.; Hwang, D. J.; Miller, D. D.; Dalton, J. T. The para substituent of S-3-(phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl- phenyl)-propionamides is a major structural determinant of in vivo disposition and activity of selective androgen receptor modulators. J. Pharmacol. Exp. Ther. 2005, 315 (1), 230-239. (Pubitemid 41380516)
4. Jinming, Z.; Bing, L.; Guoyan, G.; Jian Hui, W. Study of the impact of the T877A mutation on ligand-induced helix-12 positioning of the androgen receptor resulted in design and synthesis of novel antiandrogens. Proteins: Struct., Funct., Bioinf. 2009, 78 (3), 623-637.
5. McGinley, P. L.; Koh, J. T. Circumventing anti-androgen resistance by molecular design. J. Am. Chem. Soc. 2007, 129 (13), 3822-3823. (Pubitemid 46595493)
6. Bohl, C. E.; Gao, W.; Miller, D. D.; Bell, C. E.; Dalton, J. T. Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc. Natl. Acad. Sci. U.S.A. 2005, 102 (17), 6201-6206. (Pubitemid 40594278)
7. Marhefka, C. A.; Gao, W.; Chung, K.; Kim, J.; He, Y.; Yin, D.; Bohl, C.; Dalton, J. T.; Miller, D. D. Design, synthesis, and biol. characterization of metabolically stable selective androgen receptor modulators. J. Med. Chem. 2004, 47 (4), 993-998. (Pubitemid 38176802)
8. Magano, J.; Chen, M. H.; Clark, J. D.; Nussbaumer, T. 2-(Diethylamino)ethanethiol, a new reagent for the odorless deprotection of aromatic methyl ethers. J. Org. Chem. 2006, 71 (18), 7103-7105. (Pubitemid 44645700)
9. Krishnamurthy, S.; Aimino, D. Rapid and selective reduction of functionalized aromatic disulfides with lithium tri-tert-butoxyaluminohydride. A remarkable steric and electronic control. Comparison of various hydride reagents. J. Org. Chem. 2002, 54 (18), 4458-4462.
10. Kirkovsky, L.; Mukherjee, A.; Yin, D.; Dalton, J. T.; Miller, D. D. Chiral nonsteroidal affinity ligands for the androgen receptor. 1. Bicalutamide analogues bearing electrophilic groups in the B aromatic ring. J. Med. Chem. 2000, 43 (4), 581-590. (Pubitemid 30127153)
11. Jones, A.; Hwang, D. J.; Duke, C. B., III; He, Y.; Siddam, A.; Miller, D. D.; Dalton, J. T. Nonsteroidal selective androgen receptor modulators enhance female sexual motivation. J. Pharmacol. Exp. Ther. 2010, 334 (2), 439-448.